March 26, 2008
Halsa Pharmaceuticals Receives 250,000 Dollars From Texas ETF To Develop Therapeutic Weight-Loss Treatment
ADVERTISEMENTS
Houston-based Halsa Pharmaceuticals, Inc., has been awarded $250,000 from the Texas Emerging Technology Fund (TETF) to continue development and pilot manufacturing of a therapeutic treatment for obesity. The TETF may provide up to $1 million total investment if the company meets certain performance benchmarks.
Spread the word
Leave a Comment